Presentation
GlioCure is a preclinical-stage drug-development company specialized in neuro-oncology whose leading drug-candidate, GC01iv, is a game-changing anti-mitotic peptide for the treatment of glioblastoma (GBM) and other aggressive cancers over-expressing βIII-tubulin
Contact
Address
Institut de Biologie en Santé (PBH-IRIS) 4, rue Larrey 49933 Angers cedex 09
Website
Targeted indications : Brain cancer